[go: up one dir, main page]

FI971412L - Peptididyyliyhdisteet ja niiden terapeuttinen käyttö metalloproteaasien estäjinä - Google Patents

Peptididyyliyhdisteet ja niiden terapeuttinen käyttö metalloproteaasien estäjinä Download PDF

Info

Publication number
FI971412L
FI971412L FI971412A FI971412A FI971412L FI 971412 L FI971412 L FI 971412L FI 971412 A FI971412 A FI 971412A FI 971412 A FI971412 A FI 971412A FI 971412 L FI971412 L FI 971412L
Authority
FI
Finland
Prior art keywords
peptididyl
compounds
therapeutic use
metalloprotease inhibitors
metalloprotease
Prior art date
Application number
FI971412A
Other languages
English (en)
Swedish (sv)
Other versions
FI971412A7 (fi
FI971412A0 (fi
Inventor
John Montana
Andrew Douglas Baxter
David Alan Owen
Robert John Watson
Neil Phillipson
Original Assignee
Chiroscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9420057A external-priority patent/GB9420057D0/en
Priority claimed from GBGB9504907.8A external-priority patent/GB9504907D0/en
Priority claimed from GBGB9509431.4A external-priority patent/GB9509431D0/en
Application filed by Chiroscience Ltd filed Critical Chiroscience Ltd
Publication of FI971412A7 publication Critical patent/FI971412A7/fi
Publication of FI971412L publication Critical patent/FI971412L/fi
Publication of FI971412A0 publication Critical patent/FI971412A0/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052Val-amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043Leu-amino acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI971412A 1994-10-05 1995-10-05 Peptididyyliyhdisteet ja niiden terapeuttinen käyttö metalloproteaasien estäjinä FI971412A0 (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9420057A GB9420057D0 (en) 1994-10-05 1994-10-05 Compounds
GBGB9504907.8A GB9504907D0 (en) 1995-03-10 1995-03-10 Compounds
GBGB9509431.4A GB9509431D0 (en) 1995-05-10 1995-05-10 Compounds
PCT/GB1995/002362 WO1996011209A1 (en) 1994-10-05 1995-10-05 Peptidyl compounds and their therapeutic use as inhibitors of metalloproteases

Publications (3)

Publication Number Publication Date
FI971412A7 FI971412A7 (fi) 1997-04-04
FI971412L true FI971412L (fi) 1997-04-04
FI971412A0 FI971412A0 (fi) 1997-04-04

Family

ID=27267412

Family Applications (1)

Application Number Title Priority Date Filing Date
FI971412A FI971412A0 (fi) 1994-10-05 1995-10-05 Peptididyyliyhdisteet ja niiden terapeuttinen käyttö metalloproteaasien estäjinä

Country Status (19)

Country Link
US (2) US5994312A (fi)
EP (1) EP0784629B1 (fi)
JP (1) JP3787605B2 (fi)
CN (1) CN1193978A (fi)
AT (1) ATE179431T1 (fi)
AU (1) AU695796B2 (fi)
BR (1) BR9509237A (fi)
CA (1) CA2201639A1 (fi)
CZ (1) CZ288436B6 (fi)
DE (1) DE69509401T2 (fi)
DK (1) DK0784629T3 (fi)
ES (1) ES2133807T3 (fi)
FI (1) FI971412A0 (fi)
GR (1) GR3030751T3 (fi)
HU (1) HUT77282A (fi)
MX (1) MX9702487A (fi)
NO (1) NO971537L (fi)
PL (1) PL183510B1 (fi)
WO (1) WO1996011209A1 (fi)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2217850A1 (en) * 1995-05-10 1996-11-14 Chirotech Technology Limited Peptide compounds which inhibit metalloproteinase and tnf liberation, and their therapeutic use
WO1996035687A1 (en) * 1995-05-10 1996-11-14 Chiroscience Limited Peptidyl compounds and their therapeutic use
JPH11504646A (ja) * 1995-05-10 1999-04-27 カイロサイエンス・リミテッド 金属プロテアーゼとtnfの放出を抑制するペプチド化合物およびその治療的使用
DE69627483T2 (de) * 1995-05-10 2004-04-01 Darwin Discovery Ltd., Slough Peptidartige stoffe, die metalloproteinasen und die tnf-freisetzung hemmen, und ihre therapeutische verwendung
KR980009238A (ko) * 1995-07-28 1998-04-30 우에노 도시오 설포닐아미노산 유도체
IL123430A (en) * 1995-10-05 2001-04-30 Darwin Discovery Ltd Theo-converted peptides as inhibitors for metallic proteinases and TNF release
GB9523066D0 (en) * 1995-11-10 1996-01-10 Chiroscience Ltd Compounds and their therapeutic use
BR9611636A (pt) * 1995-11-22 1999-12-28 Darwin Discovery Ltd Compostos de mercaptoalquilpeptidila que apresentam um substituinte imdazol e seu uso como inibidores de metaloproteinases de matriz (mmp) e/ou como fator de necrose de tumores (tnf).
KR100338861B1 (ko) 1996-01-23 2003-02-20 시오노기세이야쿠가부시키가이샤 술폰화아미노산유도체및이를함유한메탈로프로테이나제저해제
US6919375B1 (en) 1996-01-23 2005-07-19 Shionogi & Co., Ltd. Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
GB9607120D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
US6811995B1 (en) * 1996-04-26 2004-11-02 Children's Medical Center Corporation Non-invasive enzyme screen for cancer
PL331369A1 (en) * 1996-07-22 1999-07-05 Monsanto Co Thiosulphonic metaloprotease inhibitors
US6747027B1 (en) 1996-07-22 2004-06-08 Pharmacia Corporation Thiol sulfonamide metalloprotease inhibitors
JP2000515153A (ja) * 1996-07-22 2000-11-14 モンサント カンパニー チオールスルホンアミド メタロプロテアーゼインヒビター
GB9616643D0 (en) * 1996-08-08 1996-09-25 Chiroscience Ltd Compounds
US6429212B1 (en) * 1996-08-16 2002-08-06 Ishihara Sangyo Kaisha Ltd. Medicinal composition
EP0933379B1 (en) * 1996-08-28 2006-03-22 Shionogi & Co., Ltd. Novel peptide derivatives having thiazolyl-alanine residue
US6953788B1 (en) 1996-09-19 2005-10-11 Aventis Pharmaceuticals Inc. 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
HUP9904165A3 (en) * 1996-09-19 2002-01-28 Aventis Pharmaceuticals Inc Br 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase and use thereof
GB9624817D0 (en) * 1996-11-28 1997-01-15 British Biotech Pharm Metalloproteinase inhibitors
SI0946166T1 (en) * 1996-12-17 2004-06-30 Warner-Lambert Company Llc Use of matrix metalloproteinase inhibitors for promoting wound healing
US6340709B1 (en) * 1996-12-17 2002-01-22 Warner-Lambert Company Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing
ES2212270T3 (es) * 1997-03-03 2004-07-16 Darwin Discovery Limited Inhibidores selectivos de metaloproteinasas matriciales (mmp) con efectos secundarios reducidos.
US6794511B2 (en) 1997-03-04 2004-09-21 G. D. Searle Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US7115632B1 (en) 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US6696449B2 (en) 1997-03-04 2004-02-24 Pharmacia Corporation Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
WO1998039326A1 (en) 1997-03-04 1998-09-11 Monsanto Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
US6638952B1 (en) 1997-03-04 2003-10-28 Pharmacia Corporation Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds
ES2206903T3 (es) 1997-03-04 2004-05-16 Monsanto Company Compuestos sulfonilicos divalentes de acido aril o heteroaril-hidroxamco.
WO1998039316A1 (en) 1997-03-04 1998-09-11 Monsanto Company N-hydroxy 4-sulfonyl butanamide compounds
US6034136A (en) * 1997-03-20 2000-03-07 Novartis Ag Certain cyclic thio substituted acylaminoacid amide derivatives
US5756545A (en) * 1997-04-21 1998-05-26 Warner-Lambert Company Biphenysulfonamide matrix metal alloproteinase inhibitors
WO1999007679A1 (en) * 1997-08-08 1999-02-18 Chiroscience Limited Peptidyl compounds having mmp and tnf inhibitory activity
US6319902B1 (en) 1997-08-22 2001-11-20 Shionogi & Co., Ltd. Peptide derivatives having thiazolyl-alanine residue
US20010039287A1 (en) 1997-11-14 2001-11-08 Thomas E Barta Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US6750228B1 (en) 1997-11-14 2004-06-15 Pharmacia Corporation Aromatic sulfone hydroxamic acid metalloprotease inhibitor
RU2250105C2 (ru) 1997-11-14 2005-04-20 Дж.Д.Сёрл ЛЛС Ароматическая сульфонгидроксамовая кислота в качестве ингибитора металлопротеаз
FI980604A0 (fi) * 1998-03-18 1998-03-18 Univ Helsinki Licensing Nya matrismetalloproteinasinhibitorer och -regulatorer
WO2000024763A1 (en) * 1998-10-23 2000-05-04 Darwin Discovery Limited Single morphic forms of known peptide metalloproteinase inhibitors
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
AU1926700A (en) * 1998-12-31 2000-07-24 Aventis Pharmaceuticals Inc. 3-(thio-substituted amido)-lactams useful as inhibitors of matrix metalloproteinase
US6329550B1 (en) 1998-12-31 2001-12-11 Aventis Pharmaceuticals Inc. Amidomalonamides useful as inhibitors of MMP of matrix metalloproteinase
US6486193B2 (en) * 1998-12-31 2002-11-26 Aventis Pharmaceuticals Inc. 3-substituted pyrrolidines useful as inhibitors of matrix metalloproteinases
US6800646B1 (en) 1999-02-08 2004-10-05 Pharmacia Corporation Sulfamato hydroxamic acid metalloprotease inhibitor
EP1157021A1 (en) 1999-02-08 2001-11-28 G.D. SEARLE & CO. Sulfamato hydroxamic acid metalloprotease inhibitor
US6583299B1 (en) 1999-05-20 2003-06-24 G.D. Searle & Co. α-amino-β-sulfonyl hydroxamic acid compounds
NL1013404C2 (nl) * 1999-10-27 2001-05-01 Dsm Nv Werkwijze voor de bereiding van een dipeptide en tussenproduct in een dergelijke werkwijze.
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US7182953B2 (en) * 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US6683093B2 (en) 2000-05-12 2004-01-27 Pharmacia Corporation Aromatic sulfone hydroxamic acids and their use as protease inhibitors
DE60101224T2 (de) 2000-05-15 2004-09-02 Darwin Discovery Ltd., Slough Hydroxamsäure-Derivate
ES2435000T3 (es) * 2000-08-25 2013-12-18 Research Corporation Technologies, Inc. Aminoácidos anticonvulsionantes para el tratamiento del dolor
CN1283314C (zh) 2000-08-31 2006-11-08 盐野义制药株式会社 抗帕金森氏病药
ATE327744T1 (de) 2001-03-20 2006-06-15 Sanol Arznei Schwarz Gmbh Neue verwendung von peptidverbindungen bei der behandlung von nicht-neuropathischem entzündungsschmerz
PT1243263E (pt) * 2001-03-21 2003-03-31 Sanol Arznei Schwarz Gmbh Nova utilizacao de uma classe peptidica de composto para o tratamento de alodinia ou de outros tipos diferentes de dor cronica ou fantasma
FR2823212B1 (fr) * 2001-04-10 2005-12-02 Inst Nat Sante Rech Med Inhibiteurs de la toxine botulique de type b
YU85403A (sh) 2001-05-11 2006-03-03 Pharmacia Corporation Aromatični sulfonski hidroksamati i njihova upotreba kao proteaznih inhibitora
JP4212470B2 (ja) 2001-06-26 2009-01-21 アムジェン フレモント インク. Opglへの抗体
US6683078B2 (en) 2001-07-19 2004-01-27 Pharmacia Corporation Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
MXPA04010555A (es) 2002-04-25 2005-02-17 Pharmacia Corp Acidos piperidinil- y piperazinil-sulfonilmetil hidroxamicos y su uso como inhibidores de proteasa.
MXPA05000171A (es) * 2002-06-25 2005-04-08 Pharmacia Corp Acido arilsulfonilhidroxamico y derivados de amida y su uso como inhibidores de la proteasa.
EP1585555A2 (en) * 2002-12-27 2005-10-19 Angiotech International Ag Compositions and methods of using collagen and mmpi
ATE457716T1 (de) 2002-12-30 2010-03-15 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
US20040259744A1 (en) * 2003-12-19 2004-12-23 Meidong Yang Skin and hair cleansers containing sulfur
CN1950101B (zh) 2004-04-16 2011-03-30 舒沃茨药物股份公司 肽化合物用于预防和治疗慢性头痛的用途
WO2006021412A2 (en) 2004-08-27 2006-03-02 Schwarz Pharma Ag Use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
WO2007141029A1 (en) * 2006-06-08 2007-12-13 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Specific protease inhibitors and their use in cancer therapy
SI2462990T1 (sl) 2006-06-15 2014-04-30 Ucb Pharma Gmbh Farmacevtski sestavek, ki obsega lakozamid in levetiracetam, s sinergističnim antikonvulzivnim učinkom
WO2008029168A2 (en) * 2006-09-08 2008-03-13 Summit Corporation Plc Treatment of duchenne muscular dystrophy
WO2009048541A2 (en) * 2007-10-05 2009-04-16 Purdue Research Foundation Compounds and methods for use in treating neoplasia and cancer
JP2012523438A (ja) 2009-04-10 2012-10-04 タフツ メディカル センター インコーポレイテッド メタロプロテイナーゼ−1(mmp−1)によるpar−1活性化
WO2013016531A2 (en) * 2011-07-26 2013-01-31 Purdue Research Foundation Compounds and methods for use in treating neoplasia and cancer
WO2013039851A1 (en) 2011-09-12 2013-03-21 Mallinckrodt Llc Optical agents for imaging and visualization of matrix metalloproteinase enzymes
CN110143892B (zh) * 2019-06-21 2022-08-12 江苏豪森药业集团有限公司 莫沙必利中间体的制备方法
CN118324664A (zh) * 2024-03-14 2024-07-12 四川鸿日医药科技有限公司 一种丝氨酸衍生物的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4113715A (en) * 1977-01-17 1978-09-12 E. R. Squibb & Sons, Inc. Amino acid derivatives
US4235885A (en) * 1979-06-25 1980-11-25 E. R. Squibb & Sons, Inc. Inhibitors of mammalian collagenase
US4263293A (en) * 1980-05-30 1981-04-21 E. R. Squibb & Sons, Inc. Heterocyclic containing amides as inhibitors of mammalian collagenase
US4382081A (en) * 1981-06-12 1983-05-03 E. R. Squibb & Sons, Inc. Inhibitors of mammalian collagenase
GB8311286D0 (en) * 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
DE3889726T2 (de) * 1987-03-17 1994-10-13 Res Corp Technologies Inc Synthetische inhibitoren von säugetier-collagenase.
WO1992022523A2 (en) * 1991-06-14 1992-12-23 Research Corporation Technologies, Inc. Peptide derivatives of collagenase inhibitor
FR2679564A1 (fr) * 1991-07-23 1993-01-29 Inst Nat Sante Rech Med Nouveaux acylmercaptoalcanoldipeptides, leur preparation et les compositions qui les contiennent.
AU687436B2 (en) * 1993-08-23 1998-02-26 Immunex Corporation Inhibitors of TNF-alpha secretion
US5455262A (en) * 1993-10-06 1995-10-03 Florida State University Mercaptosulfide metalloproteinase inhibitors
GB9323165D0 (en) * 1993-11-10 1994-01-05 Chiros Ltd Compounds

Also Published As

Publication number Publication date
CZ99697A3 (en) 1997-09-17
AU695796B2 (en) 1998-08-20
CZ288436B6 (en) 2001-06-13
PL319503A1 (en) 1997-08-18
CN1193978A (zh) 1998-09-23
EP0784629A1 (en) 1997-07-23
BR9509237A (pt) 1997-10-21
AU3612795A (en) 1996-05-02
CA2201639A1 (en) 1996-04-18
US6180611B1 (en) 2001-01-30
PL183510B1 (pl) 2002-06-28
DE69509401T2 (de) 1999-08-19
WO1996011209A1 (en) 1996-04-18
NO971537L (no) 1997-06-04
DK0784629T3 (da) 1999-10-25
FI971412A7 (fi) 1997-04-04
MX9702487A (es) 1998-04-30
ATE179431T1 (de) 1999-05-15
DE69509401D1 (de) 1999-06-02
EP0784629B1 (en) 1999-04-28
US5994312A (en) 1999-11-30
ES2133807T3 (es) 1999-09-16
JPH10507170A (ja) 1998-07-14
NO971537D0 (no) 1997-04-04
GR3030751T3 (en) 1999-11-30
HUT77282A (hu) 1998-03-30
FI971412A0 (fi) 1997-04-04
JP3787605B2 (ja) 2006-06-21

Similar Documents

Publication Publication Date Title
FI971412L (fi) Peptididyyliyhdisteet ja niiden terapeuttinen käyttö metalloproteaasien estäjinä
FI961976A7 (fi) Peptidyyliyhdisteitä ja niiden terapeuttinen käyttö metalloproteinaasien inhibiittoreina
FI972160A7 (fi) Matriisimetalloproteaasi-inhibiittorit
FI955051L (fi) Heterosyklisiä yhdisteitä ja niiden valmistus ja käyttö
FI970762L (fi) Terapiassa käyttökelpoiset spiroatsabisykliset yhdisteet
EE9900171A (et) Heteroarüülsuktsiinamiidid ja nende kasutamine metalloproteinaaside inhibiitoritena
FI971969A0 (fi) Peräpukamien hoitoon tarkoitettuja koostumuksia ja käyttömenetelmä
FI965039A7 (fi) Uusia trombiini-inhibiittoreita, niiden valmistus ja käyttö
FI963597L (fi) Isoprenyylitransferaasi-inhibiittoreita
FI963238A7 (fi) Heteroaromaattisia oksatsoli yhdisteitä ja niiden käyttö
DK0769017T3 (da) Terapeutiske forbindelser
FI972062A7 (fi) Substituoituja 4-biaryylivoi- tai 5-biaryylipentaanihappoja ja johdannaisia matriisimetalliproteaasi-inhibiittoreina
FI962800L (fi) Fenyyliheterosyklisiä yhdisteitä COX-2 inhibiittoreina
EE9800459A (et) Spiro-piperidiini derivaadid ja nende kasutamine terapeutiliste toimeainetena
ITMI942025A0 (it) Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia
FI970317A7 (fi) Antiproliferatiivisina aineina ja Garft-inhibiittoreina käyttökelpoisia yhdisteitä
ID18679A (id) Penggunaan terapi lanjutan
FI971750A7 (fi) Koostumuksia multippeliskleroosia varten ja sen hoito
FI972245A0 (fi) Meso-monojodisubstituoidut tetramakrosykliset yhdisteet sekä niiden valmistus- ja käyttömenetelmät
FI951060A7 (fi) Formulaatioita ja hoitomenetelmiä
FI964936L (fi) Bentsopyraaneja ja niiden käyttö terapeuttisina aineina
FI964482L (fi) Amidijohdannaisia ja niiden käyttö lääkkeenä
FI963130A7 (fi) Heterosykliset yhdisteet sekä niiden valmistus ja käyttö
FI974609A7 (fi) Uusia heterosyklisiä yhdisteitä kivun hoitoon ja niiden käyttö
FI970318L (fi) Antiproliferatiivisina aineina ja Garft-inhibiitoreina käyttökelpoisia yhdisteitä

Legal Events

Date Code Title Description
MA Patent expired